TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer

International Journal of Cancer

Volumn 117, Issue 3, 2005, Pages 370-375

  Kelsey, Karl T ^a   Hirao, Tomoko ^a   Hirao, Shuya ^a   Devi Ashok, Tara ^a   Nelson, Heather H ^a   Andrew, Angeline ^b   Colt, Joanne ^c   Baris, Dalsu ^c   Morris, J Steven ^d   Schned, Alan ^b   Karagas, Margaret ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

Arsenic; Bladder cancer; Hair dye; Occupation

Indexed keywords

ARSENIC; CARCINOGEN; PROTEIN P53;

ADULT; ARTICLE; BLADDER CANCER; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SMOKING;

AMINO ACID SUBSTITUTION; CARCINOGENS; FEMALE; HAIR DYES; HUMANS; MALE; MUTAGENS; MUTATION; NEOPLASM INVASIVENESS; OCCUPATIONAL EXPOSURE; SMOKING; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 23844550076     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21195     Document Type: Article

References (55)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Silverman D, Morrison A, Devesa S. Bladder cancer. In: Schottenfeld D, Fraumeni JJ. Cancer epidemiology and prevention, 2nd ed. New York: Oxford University Press, 1996.1156-79.
3. Ron E, Preston DL, Mabuchi K, Thompson DE, Soda M. Cancer incidence in atomic bomb survivors. Part IV: Comparison of cancer incidence and mortality. Radiat Res 1994;137:598-112.
4. Gago-Dominguez M, Bell DA, Watson MA, Yuan JM, Castelao JE, Hein DW, Chan KK, Coetzee GA, Ross RK, Yu MC. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis 2003;24:483-9.
5. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC, Giovannucci EL. Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999;340:1390-7.
6. Brown LM, Zahm SH, Hoover RN, Fraumeni JF Jr. High bladder cancer mortality in rural New England (United States): an etiologic study. Cancer Causes Control 1995;6:361-8.
7. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
8. Spruck CH 3rd, Rideout WM 3rd, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC, et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 1993;53:1162-6.
9. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, Dubeau L, Nichols PW, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
10. Berggren P, Steineck G, Adolfsson J, Hansson J, Jansson O, Larsson P, Sandstedt B, Wijkstrom H, Hemminki K. p53 mutations in urinary bladder cancer. Br J Cancer 2001;84:1505-11.
11. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 2003;169:1219-28.
12. Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003;170:438-41.
13. Larsson P, Wijkstrom H, Thorstenson A, Adolfsson J, Norming U, Wiklund P, Onelov E, Steineck G. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 2003;37:195-201.
14. Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, Hamazaki S, Toguchida J, Ishizaki K, Fujita J, Sugiyama T, Yoshida O. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 1993;53:3795-9.
15. Kannio A, Ridanpaa M, Koskinen H, Partanen T, Anttila S, Collan Y, Hietanen E, Vainio H, Husgafvel-Pursiainen K. A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos. Cancer Epidemiol Biomarkers Prev 1996;5:33-9.
16. LaRue H, Allard P, Simoneau M, Normand C, Pfister C, Moore L, Meyer F, Tetu B, Fradet Y. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis 2000;21:101-6.
17. Moore LE, Smith AH, Eng C, DeVries S, Kalman D, Bhargava V, Chew K, Ferreccio C, Rey OA, Hopenhayn C, Biggs ML, Bates MN, et al. P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis 2003;24:1785-91.
18. Szymanska K, Hainaut P. TP53 and mutations in human cancer. Acta Biochim Pol 2003;50:231-8.
19. Andrew AS, Schned AR, Heaney JA, Karagas MR. Bladder cancer risk and personal hair dye use. Int J Cancer 2004;109:581-6.
20. Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect 1998;106(Suppl 4):1047-50.
21. Karagas MR, Stukel TA, Morris JS, Tosteson TD, Weiss JE, Spencer SK, Greenberg ER. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am J Epidemiol 2001;153:559-65.
22. Karagas MR, Tosteson TD, Blum J, Klaue B, Weiss JE, Stannard V, Spate V, Morris JS. Measurement of low levels of arsenic exposure: a comparison of water and toenail concentrations. Am J Epidemiol 2000;152:84-90.
23. Garland M, Morris JS, Rosner BA, Stampfer MJ, Spate VL, Baskett CJ, Willett WC, Hunter DJ. Toenail trace element levels as biomarkers: reproducibility over a 6-year period. Cancer Epidemiol Biomarkers Prev 1993;2:493-7.
24. Nelson HH, Kelsey KT, Bronson MH, Mott LA, Karagas MR. Fas/APO-1 promoter polymorphism is not associated with non-melanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2001;10:809-10.
25. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992;326:1301-8.
26. Colt JS, Baris D, Stewart P, Schned AR, Heaney JA, Mott LA, Silverman D, Karagas M. Occupation and bladder cancer risk in a population-based case-control study in New Hampshire. Cancer Causes Control 2004;15:759-69.
27. Xu X, Stower MJ, Reid IN, Garner RC, Burns PA. A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. Cancer Epidemiol Biomarkers Prev 1997;6:611-6.
28. Ryk C, Berggren P, Kumar R, Hemminki K, Larsson P, Steineck G, Lambert B, Hou SM. Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutatipnal spectrum in bladder tumours. Int J Cancer 2005;113:761-8.
29. George B, Datar R, Wu H, Beil SJ, Patten N, Cai J, Groshen S, Cote RJ. Complete p53 multi-exon sequencing by gene chip complements use of p53 immunohistochemistry for prediction of clinical outcome in invasive bladder cancer. Proc Am Assoc Cancer Res, 2004.
30. Cox D. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
31. Kelsey KT, Hirao T, Schned A, Hirao S, Devi-Ashok T, Nelson HH, Andrew A, Karagas MR. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer 2004;90:1572-6.
32. Vet JA, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FM, Schalken JA. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest 1995;73:837-43.
33. Babjuk M, Soukup V, Mares J, Duskova J, Sedlacek Z, Trkova M, Pecen L, Dvoracek J, Hanus T, Kocvara R, Novak J, Povysil C. The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. Int Urol Nephrol 2002;34:495-501.
34. Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol 1999;162:1496-501.
35. Esrig D, Spruck CH 3rd, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
36. Gao JP, Uchida T, Wang C, Jiang SX, Matsumoto K, Satoh T, Minei S, Soh S, Kameya T, Baba S. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int J Oncol 2000;16:469-75.
37. Abdel-Fattah R, Challen C, Griffiths TR, Robinson MC, Neal DE, Lunec J. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998;77:2230-8.
38. Oyasu R, Nan L, Szumel RC, Kawamata H, Hirohashi S. p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism. Mod Pathol 1995;8:170-6.
39. Zhang ZF, Sarkis AS, Cordon-Cardo C, Dalbagni G, Melamed J, Aprikian A, Pollack D, Sheinfeld J, Herr HW, Fair WR, Reuter VE, Begg C. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol Biomarkers Prev 1994;3:19-24.
40. Pacchioni D, Martone T, Ghisolfi G, Bussolati G, Tizzani A, Casetta G, Vineis P. Tobacco smoke, recurrences, and p53/bcl-2 expression in bladder cancer. Carcinogenesis 1997;18:1659-61.
41. Romano G, Garagnani L, Boninsegna A, Ferrari P, Flamini G, De Gaetani C, Sgambato A, Giovanni F, Curigliano G, Ferretti G, Cittadini A, Trentini G. Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma. Anticancer Res 1999;19:4571-6.
42. Bernardini S, Adessi GL, Chezy E, Billerey C, Carbillet JP, Bittard H. Influence of cigarette smoking on P53 gene mutations in bladder carcinomas. Anticancer Res 2001;21:3001-4.
43. Schroeder JC, Conway K, Li Y, Mistry K, Bell DA, Taylor JA. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Res 2003;63:7530-8.
44. Olshan AF, Weissler MC, Pei H, Conway K. p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. Cancer Epidemiol Biomarkers Prev 1997;6:499-504.
45. Henley SJ, Thun MJ. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer 2001;94:903-6.
46. Hennekens CH, Speizer FE, Rosner B, Bain CJ, Belanger C, Peto R. Use of permanent hair dyes and cancer among registered nurses. Lancet 1979;1:1390-3.
47. Howe GR, Burch JD, Miller AB, Cook GM, Esteve J, Morrison B, Gordon P, Chambers LW, Fodor G, Winsor GM. Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst 1980;64:701-13.
48. Czene K, Tiikkaja S, Hemminki K. Cancer risks in hairdressers: assessment of carcinogenicity of hair dyes and gels. Int J Cancer 2003;105:108-12.
49. Arrhenius E, Boyland E, Brown SM, Craig AW, Davies JM, Dzhioev FK, Flamm WG, Garner RC, Kriek E, Krowke R, Loprieno N, Neumann HG, et al. Some aromatic amines and related nitro compounds-hair dyes, coloring agents and miscellaneous industrial chemicals. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man. Lyon: IARC, 1977.16.
50. Kadlubar FF. A transversion mutation hypothesis for chemical carcinogenesis by N2-substitution of guanine in DNA. Chem Biol Interact 1980;31:255-63.
51. Nagao M, Ushijima T, Wakabayashi K, Ochiai M, Kushida H, Sugimura T, Hasegawa R, Shirai T, Ito N. Dietary carcinogens and mammary carcinogenesis. Induction of rat mammary carcinomas by administration of heterocyclic amines in cooked foods. Cancer 1994;74:1063-9.
52. Karagas MR, Tosteson TD, Morris JS, Demidenko E, Mott LA, Heaney JA, Schned AR. Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control 2005;15:465-72.
53. Hamadeh HK, Vargas M, Lee E, Menzel DB. Arsenic disrupts cellular levels of p53 and mdm2: a potential mechanism of carcinogenesis. Biochem Biophys Res Commun 1999;263:446-9.
54. Castren K, Ranki A, Welsh JA, Vahakangas KH. Infrequent p53 mutations in arsenic-related skin lesions. Oncol Res 1998;10:475-82.
55. Kligerman AD, Doerr CL, Tennant AH, Harrington-Brock K, Allen JW, Winkfield E, Poorman-Allen P, Kundu B, Funasaka K, Roop BC, Mass MJ, DeMarini DM. Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ Mol Mutagen 2003;42:192-205.